Skip to main content
NexImmune, Inc.Portfolio

NexImmune Granted Key US Patent for Core E+E Technology

By December 11, 2018March 25th, 2021No Comments

GAITHERSBURG, Md., Dec. 11, 2018 (GLOBE NEWSWIRE) — NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the United States Patent and Trademark Office has issued a new method of use patent to Johns Hopkins University related to the Company’s E+E (T cell Enrichment and Enhancement) technology for which NexImmune holds an exclusive license from Johns Hopkins. This further enhances the company’s AIM technology intellectual property portfolio and provides broad intellectual property rights protecting key aspects of the company’s lead product AIM ACT, an adoptive T cellular therapy for the treatment of cancer.

“Using our proprietary E+E technology to generate antigen-specific T cells represents a uniquely differentiated approach to expanding polyclonal T cells that are highly antigen-specific, highly polyfunctional and with a phenotypic composition optimized for anti-tumor cytotoxicity, proliferative capacity and long-term immunologic memory. We believe our AIM E+E generated T cell products have the potential to address some of the clinical limitations observed with currently available genetically modified T cell therapies.  Our hope is that these differences translate into meaningful benefit for patients suffering from a variety of hematological malignancies,” commented Scott Carmer, Chief Executive Officer of NexImmune. “Ensuring a robust intellectual property position around E+E is inherent to advancing the program and the claims granted in this patent exemplify the novel science behind this exciting technology.”

U.S. patent 10,098,939 adds to previously issued U.S. and international counterpart patents and patent applications that form NexImmune’s AIM patent portfolio. Claims were granted on the ability of E+E to expand large numbers of antigen-specific T cells from the body’s endogenous T cell repertoire. Preclinical studies have demonstrated that cells generated using E+E have a large proportion of highly functional central and effector memory T cells which the company believes will provide both a potent immediate therapeutic benefit for cancer patients and an enhanced durability of response compared to currently approved adoptive T cell therapies. NexImmune plans to advance its AIM ACT platform into early phase clinical trials in 2019.

About NexImmune

NexImmune is a biopharmaceutical company with a mission to help cure cancer by directing T cell function using precision technology and personalized therapeutics. The Company’s proprietary AIM Technology uses artificial Antigen Presenting Cells (aAPC) to create highly targeted T cell-based immunotherapies. In preclinical studies, aAPC have demonstrated the ability to clear established tumors by expanding antigen-specific T cells when injected directly (in vivo) or when used as part of an ex vivo cellular expansion system.  For more information visit:

The Leukemia & Lymphoma Society is a NexImmune partner for the clinical development of AIM ACT.

Rapha Capital Management, LLC is providing this website for informational purposes only. Nothing on this website is intended to constitute, or should be deemed to be, financial advisory, legal, tax, accounting or other professional advice to you or any other party; be an opinion of the appropriateness or suitability of any investment; or constitute an offer to sell or solicitation of an offer to buy any security or investment. This website and its content (collectively, “Content”) is intended for general informational purposes only and should not be acted upon without first obtaining financial advisory, legal, tax, accounting or other professional advice from your consultant or other professional with respect to your own personal investment objectives, financial circumstances and needs. Nothing on the Site shall be considered a recommendation or solicitation to buy or an offer to sell a security to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Any investment decisions you may make on the basis of any information found on this web site is your sole responsibility. Prior to making any investment or hiring any investment manager you should consult with a professional financial advisor, legal and tax advisor to assist in due diligence as may be appropriate and determining the appropriateness of the risk associated with a particular investment. In no event shall Rapha Capital Management, LLC be responsible or liable for the correctness of any such material or for any damage or lost opportunities resulting from use of these data.